Compared to tumors in the vehicle (Fig. 6A, E) or adriamycin treatment group (Fig. 6B, E), both eFT-508 monotherapy (Fig. 6C, E) and combination therapy (Fig. 6D, E ) significantly downregulated PD-L1 + and PD-L2 + breast tumor cells. Here, PDCD1LG2 is linked to breast neoplasm.